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A B S T R A C T The molecular basis for the aberrant catecholamine responsiveness of the adenylate cyclase of adrenocortical carcinoma 494 was explored. The adenylate cyclase of this corticosteroid-producing, transplanted, adrenal cancer of the rat was stimulated not only by adrenocorticotropic hormone and fluoride, but also by the f8-adrenergic agonist, iso- (-) [3H]dihydroalprenolol with an equilibrium dissociation constant of 2.1 nM. Adrenergic agonists competed for the binding sites in an order of potency, [(-)isoproterenol > (-)epinephrine -(-)norepinephrinel, paralleling their order of potency as f8-adrenergic agonists. The f8-adrenergic antagonist, (-)propranolol, competed for binding, causing half-maximal inhibition of specific binding at a concentration of 6 nM. The a-adrenergic antagonist, phentolamine, and several catecholamine metabolites and precursors did not effectively compete for the binding sites at high concentrations. Binding was stereospecific, the (+)stereoisomers of ,B-adrenergic agonists and antagonists requiring 40-to 300-fold higher concentrations than the corresponding (-)stereo- INTRODUCTION The biological effects of many hormones are mediated by increases in the intracellular cyclic AMP levels in the responding tissue. Cyclic AMP-mediated responses of a hormonally sensitive tissue are elicited only by those hormones which activate the membrane-bound adenylate cyclase in that tissue. In the adrenal cortex, the binding of adrenocorticotropic hormone (ACTH) to specific receptors which are functionally coupled to adenylate cyclase (1) Ci/mmol) was prepared by New England Nuclear (Boston, Mass.) by catalytic reduction of (-)alprenolol (Hassle Pharmaceuticals, Molndal, Sweden) with tritium gas using paladium as a catalyst. The labeled material is homogeneous in six different chromatographic systems as detailed elsewhere (9) and is indistinguishable from unlabeled dihydroalprenolol. The structure of (-) [3H]dihydroalprenolol is identical to that of unlabeled dihydroalprenolol as determined by mass spectroscopy. The labeled compound as well as unlabeled dihydroalprenolol have been demonstrated to be potent antagonists of isoproterenol-stimulated adenylate cyclase (9) .
Other compounds used in this study were: (-)isoproterenol bitartrate, (-)epinephrine bitartrate, (-)norepinephrine bitartrate, (+)normetanephrine and dihydroxymandelic acid (Sigma Chemical Co., St. Louis, Mo.); (+)isoproterenol bitartrate, (+)epinephrine bitartrate, (+)norepinephrine bitartrate (Winthrop Laboratories, New York); (-) and (+) propranolol hydrochloride (Ayerst Laboratories, New York); and phentolamine mesylate (Ciba Pharmaceutical Company, Summit, N. J.) and pyrocatechol (Mann Chemical Corp., Louisville, Ky.).
Tissue preparation. Adrenocortical carcinoma 494, which has previously been characterized morphologically (10) and metabolically (11) , was maintained by transplantation in male Sprague-Dawley rats in the laboratory of Dr. R. L. Ney as previously described (12) . Normal adrenals were obtained from male Sprague-Dawley rats weighing 200-250 g. For adenylate cyclase assays, normal and tumor tissues were homogenized in a buffer composed of 62.2 mM Tris-HCl, pH 7.4, and 15.5 mM theophyline as previously described (2) . The crude homogenate was centrifuged at 1,000 g for 10 min and the pellet was then resuspended in buffer (discussed below) for use in the adenylate cyclase assay. This membrane preparation has previously (2) been shown to possess the highest adenylate cyclase activity of several fractions tested from normal and tumor tissue. Membranes for (-) [3H]dihydroalprenolol binding assays were prepared by homogenization in cold (40C) buffer containing 0.25 M sucrose, 5 mM Tris-HCI (pH 7.4), and 1 mM MgCl2, by using a Potter-Elvejhem homogenizer (20 strokes) with a motor-driven Teflon pestle at high speed. The homogenate was centrifuged at 300 g for 10 min and the pellet was discarded. The supernate was centrifuged at 25,000 g for 10 min and the resulting pellet was washed twice in ice-cold wash buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2) by resuspension and centrifugation. The final pellet was resuspended in wash buffer for use in the binding assay.
Adenylate cyclase and (-)[3Hldihydroalprenolol binding assays. Adenylate cyclase activity of normal adrenal and tumor membranes was assayed as previously described (13) . Incubations were performed in a 50-IAI volume which contained 40 mM TrisHCl (pH 7.6), 3 (Fig. 1A) . Similarly, 20 mM of sodium fluoride stimulated normal adrenal (5,400% above basal) and adrenocortical tumor (1,090%o above basal) adenylate cyclase activity (not shown). By contrast, the /8-adrenergic agonist, isoproterenol (10-4M), caused virtually no stimulation of the normal adrenal cyclase while stimulating the tumor adenylate cyclase 220%o above basal activity (Fig. 1B) (Fig. 3) (-) [3H]dihydroalprenolol. The negative reciprocal ofthe slope of the plot provided an estimate of the equilibrium dissociation constant (2.1 nM) for the interaction of dihydroalprenolol with its binding sites on the tumor membranes. This value is consistent with the reported dissociation constant (5-9 nM) of alprenolol as a 83-adrenergic antagonist of catecholamine-stimulated adenylate cyclase in a variety of tissues (4) (5) (6) . From the intercept of the Scatchard plot (Fig. 3) with the abscissa, the number of binding sites (0.094 pmol/mg protein) on the tumor membranes was calculated. This is comparable to the number of (-)[3H]dihydroalprenolol binding sites found previously (5-8) in non-neoplastic mammalian tissues known to possess 8-adrenergic receptors. Data points at low bound-to-free values on the Scatchard plot (Fig. 3) were difficult to obtain because of the large amount of nonspecific binding present when high concentrations of radioligand were used.
The specificity of the binding sites for adrenergic agonists and antagonists was assessed by testing the ability of these agents to compete for (-) [3H]dihydroalprenolol binding sites. The binding displayed a typical /3-adrenergic specificity. Adrenergic agonists (Fig. 4) competed for the binding sites in an order of potency, [(-)isoproterenol > (-)epinephrine -(-)-norepinephrine], consistent with the potency order of these compounds as f8-adrenergic agonists. This /3-adrenergic pattern has been previously reported for these compounds as activators of the tumor, adenylate cyclase (3). The f8-adrenergic agonists competed for the binding sites stereospecifically (Fig. 4) , the (+)-stereoisomers requiring 40-300-fold higher concentrations than the corresponding (-)stereoisomers to inhibit an equivalent amount of binding. The f3-adrenergic antagonist, (-)-propranolol, potently competed for the binding sites (Fig. 5) causing half-maximal inhibition of binding at a concentration of 6 nM. This is consistent with the previously reported (5, 17, 18) dissociation constant (3-9 nM) of propranolol for inhibition of catecholamine-stimulated adenylate cyclase in mammalian tissue. The (+)stereoisomer of propranolol ( 
